http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Sang Ho Rha,Un Ki Kim,Jisim Jung,Hyo Kyeom Kim,Yoon Soo Jung,Eun Suk Hwang,Yoon Jang Chung,Mijung Lee,Jung-Hae Choi,Cheol Seong Hwang IEEE 2013 IEEE transactions on electron devices Vol.60 No.3
<P>Asymmetric Schottky contact thin-film-transistors (ASC-TFTs) with an amorphous- In<SUB>2</SUB>Ga<SUB>2</SUB>ZnO<SUB>7</SUB> channel were fabricated, and their operation characteristics were examined. Ti, Ni, and Pt were evaluated as source/drain metal, and the variations in the device performance were analyzed in terms of energy level and bias polarity, which were carefully simulated to understand the influence of the contact properties on the device performance. The contact nature largely influenced the distribution of potential under the given gate and drain biases, as well as the accompanying carrier accumulation layer and current path formation. Schottky-type contact induced conduction path formation even on the back surface of the channel when drain voltage was high even with sufficiently high gate bias being applied. Based on these results, by applying different metal for each source and drain metal, ASC-TFTs integrating TFTs and Schottky diodes were fabricated, which showed a rectification ratio of drain current higher than 10<SUP>8</SUP> according to the bias direction. In addition, the transfer and output characteristics of ASC-TFTs were evaluated for various operation regimes, and the roles of the Schottky junction in device operation were studied in detail.</P>
Sang Sun Lee,Won Yu Kang,Dong In Nam,Il Hyung Jung,Chung Kang,Hong Ju An,Ho Yeong Song,Hoon Kang,Sang Cheol Cho,Sun Ho Hwang,Wan Kim 조선대학교 의학연구소 2014 The Medical Journal of Chosun University Vol.39 No.2
May-Thurner syndrome is associated with deep vein thrombosis resulting from chronic compression of the iliac vein against the lumbar vertebrae caused by the overlying common iliac artery. Stent insertion into the compressed lesion is used in treatment of May-Thurner syndrome. Various complications can occur during angioplasty while using a stent. Among these complications, shrinkage of the vein below the stent, a rare complication, was observed in our hospital during treatment of a patient with May-Thurner syndrome. Different complications can occur when venous angioplasty is performed, unlike that when arterial angioplasty is performed.
Investigation of detection wavelength of Quantum Well Infrared-Photodetector
Sung Ho Hwang,Jae Gu Lim,Jin Dong Song,Jae Cheol Shin,Du Chang Heo,최원준 한국진공학회 2015 Applied Science and Convergence Technology Vol.24 No.6
We report on GaAs/AlGaAs quantum well infrared photodetectors (QWIPs) that can cover the spectral range of 3.6-25 μm. One advantage of the GaAs QWIPs is the wavelength tenability as a function of their structural parameters. We have performed a systematic calculation on the detection wavelength of a typical GaAs/AlxGa1-xAs multi-quantum-well photodetector, with the aluminum mole fraction (x) of AlxGa1-xAs barrier in the range of 0.15- 0.43 and the quantum-well width range from 30 to 60 Å. Design and fabrication of a QWIP based on GaAs/Al0.23Ga0.77As structure with 37 Å-thick well width has been carried out. The calculated operation wavelength of the QWIP is in a good agreement with the experimental data taken by photo response and activation energy calculation from thermal quenching of integrated photoluminescence.
( Sang Youn Hwang ),( Seon-mi Lee ),( Jung Woo Im ),( Ki Jeong Jeon ),( Cheol-won Choi ),( Kyung-su Kim ),( Wan Jeon ) 대한간암학회 2019 대한간암학회지 Vol.19 No.1
Sorafenib is a well-known approved systemic therapeutic agent used in patients with advanced hepatocellular carcinoma (HCC). Regorafenib and nivolumab are approved as second-line therapeutic drugs in patients showing disease progression after sorafenib therapy. However, there is no established third- or fourth-line therapy in patients with progression after regorafenib or nivolumab treatment. Recently, the combination of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICPIs) has been attempted as a firstline treatment strategy in advanced HCC patients based on the hypothesis that combination therapy may overcome resistance in ICPI monotherapy. On the basis of this suggestion, we herein describe the case of an HCC patient demonstrating macrovascular invasion, whereby partial remission was achieved via the combination of sorafenib and nivolumab following disease progression after nivolumab therapy. Further studies on the combination of TKIs and ICPIs are necessary to determine ways to manage HCC patients showing disease progression after ICPI therapy. (J Liver Cancer 2019;19:74-78)
Sang Ho Rha,Jisim Jung,Yoonsoo Jung,Yoon Jang Chung,Un Ki Kim,Eun Suk Hwang,Byoung Keon Park,Tae Joo Park,Jung-Hae Choi,Cheol Seong Hwang IEEE 2012 IEEE transactions on electron devices Vol.59 No.12
<P>The transmission-line method (TLM) was adopted to clarify the causes of device performance variation according to the source/drain metal electrode and device structure of a thin-film transistor using an amorphous indium-gallium-zinc-oxide channel. Using the TLM, the channel characteristics independent of contact resistance were extracted for the two different contact metals, i.e., Ti and Mo. Based on these results, the mobility characteristics were compared in terms of device scaling and contact structure in the source/drain overlap region. In addition, the transport characteristics according to the contact structure of the source/drain metal electrode were investigated in detail and reproduced using the simulation model.</P>
Hwang Yu-Na,Kwon In-Seo,Park Ju-Hee,Na Han-Heom,Kwon Tae-Hyung,Park Jin-Sung,Kim Keun-Cheol 한국유전학회 2023 Genes & Genomics Vol.45 No.12
Background Δ9-Tetrahydrocannabinol (Δ9-THC) is a principal psychoactive extract of Cannabis sativa and has been traditionally used as palliative medicine for neuropathic pain. Cannabidiol (CBD), an extract of hemp species, has recently attracted increased attention as a cancer treatment, but Δ9-THC is also requiring explored pharmacological application. Objective This study evaluated the pharmacological effects of Δ9-THC in two human colorectal cancer cell lines. We investigated whether Δ9-THC treatment induces cell death in human colorectal cancer cells. Methods We performed an MTT assay to determine the pharmacological concentration of Δ9-THC. Annxein V and Western blot analysis confirmed that Δ9-THC induced apoptosis in colorectal cancer cells. Metabolic activity was evaluated using MitoTracker staining and ATP determination. We investigated vesicle formation by Δ9-THC treatment using GW9662, known as a PPARγ inhibitor. Results The MTT assay showed that treatment with 40 μM Δ9-THC and above inhibited the proliferation of colorectal cancer cells. Multiple intracytoplasmic vesicles were detected upon microscopic observation, and fluorescence-activated cell sorting analysis showed cell death via G1 arrest. Δ9-THC treatment increased the expression of cell death marker proteins, including p53, cleaved PARP-1, RIP1, and RIP3, suggesting that Δ9-THC induced the death of colorectal cancer cells. Δ9-THC treatment also reduced ATP production via changes in Bax and Bcl-2. Δ9-THC regulated intracytoplasmic vesicle formation by modulating the expression of PPARγ and clathrin, adding that antiproliferative activity of Δ9-THC was also affected. Conclusion In conclusion, Δ9-THC regulated two functional mechanisms, intracellular vesicle formation and cell death. These findings can help to determine how cannabinoids can be used most effectively to improve the efficacy of cancer treatment.
Hwang, Mi-Hye,Kim, Jung Eun,Kim, Sang-Yeob,Kalimuthu, Senthilkumar,Jeong, Shin Young,Lee, Sang-Woo,Lee, Jaetae,Ahn, Byeong-Cheol Hindawi Publishing Corporation 2015 BioMed research international Vol.2015 No.-
<P>The aim of the present study is to establish a bacterial clone capable of secreting an integrin <I>α</I>v<I>β</I>3 targeting probe with bioluminescent and fluorescent activities, and to verify its specific targeting and optical activities using molecular imaging. A bacterial vector expressing a fusion of secretory Gaussia luciferase (sGluc), mCherry, and RGD (sGluc-mCherry-RGDX3; GCR), and a control vector expressing a fusion of secretory <I>Gaussia luciferase</I> and mCherry (sGluc-mCherry; GC) were constructed. The GCR and GC proteins were expressed in <I>E. coli</I> and secreted into the growth medium, which showed an approximately 10-fold higher luciferase activity than the bacterial lysate. Successful purification of GCR and GC was achieved using the 6X His-tag method. The GCR protein bound with higher affinity to U87MG cells than CHO cells in confocal microscopy and IVIS imaging, and also showed a high affinity for integrin <I>α</I>v<I>β</I>3 expressing tumor xenografts in an <I>in vivo</I> animal model. An <I>E. coli</I> clone was established to secrete an integrin <I>α</I>v<I>β</I>3 targeting imaging probe with bioluminescent and fluorescent activities. The probe was produced feasibly and at low cost, and has shown to be useful for the assessment of angiogenesis <I>in vitro</I> and <I>in vivo</I>.</P>
Differential Benefit of Statin 2ndary Prevention of AMI according to level of TG and HDL cholesterol
( Sang Woo Jeong ),( Wan Kim ),( Sun Ho Hwang ),( Won Yu Kang ),( Sang Cheol Cho ),( Kyung Hwan Kim ),( Gyu Ik Lee ),( Young Eun Jo ),( Myung Ho Jeong ),( Young Keum Ahn ) 대한내과학회 2015 대한내과학회 추계학술대회 Vol.2015 No.1
Background: The benefit of statin in acute myocardial infarction (MI) was well established. However, there were few studies about the differential efficacy of statin according to the baseline level of triglyceride and high-density lipoprotein (HDL)-cholesterol. Objective: To address the efficacy of statin in secondary prevention of MI according to the level of triglyceride and HDL-cholesterol on admission. Methods: The 36580 acute MI patients were enrolled from November 2005 to August 2012. Total patients were divided according to level of triglyceride and HDL cholesterol on admission and evaluated the efficacy of statin in patients with no lipid component of metabolic syndrome (Group A; n=15,461) (HDL cholesterol ≥40 mg/dL & triglyceride <150 mg/dL) and both components of metabolic syndrome (Group B; n=4,399)(HDL<0.001). However, the efficacy of statin was not prominent in Group B (HR=0.987; 95% CI; 0.708-1.376; p=0.939). After propensity matching, the survival analysis revealed that statin therapy reduced the risk of MACE in group A (HR=0.752, 95% CI; 0.609-0.929, p=0.008). This result was mainly due to reduction of cardiac death (HR=0.628, 95% CI; 0.420-0.938, p=0.023). Multivariate analysis revealed that use of statin contributed independently to improvement of clinical outcome in only Group A (HR=0.692, CI; 0.543-0.882, p=0.003). Conclusions: The long-term benefit ofstatin was not prominent in acute MI patients with lipid profiles of metabolic syndrome. Therefore, different lipid-lowering strategy is necessary in patients with low HDL and high triglyceride.